Velphoro Shortage: What Providers and Prescribers Need to Know in 2026

While Velphoro (sucroferric oxyhydroxide) is not on the FDA or ASHP drug shortage list, many nephrologists, PCPs, and dialysis care teams are fielding increasing calls from patients who cannot access their prescribed phosphate binder. This guide consolidates everything prescribers need to know about Velphoro access in 2026 — including the distribution shift caused by ESRD PPS changes, prior authorization considerations, patient support programs, and clinically appropriate alternatives.

The Core Issue: ESRD PPS Inclusion Creates Distribution Confusion

Effective January 1, 2025, phosphate binders — including Velphoro — were incorporated into the Medicare ESRD Prospective Payment System (PPS) bundle. This fundamentally changed how Medicare fee-for-service ESRD patients receive their phosphate binders: through their dialysis organization rather than a retail or specialty pharmacy.

Clinical implications for your practice:

• Medicare fee-for-service ESRD patients should receive Velphoro at no additional copay through their dialysis facility. There should be no additional prescription or PA required for this population.

• Patients with pending Medicare eligibility (new to dialysis within 90 days) may receive up to 90 days of Velphoro at no cost through Fresenius Medical Care's patient program during the enrollment gap.

• Certain Medicare Advantage beneficiaries and patients with commercial insurance as the primary payer may not receive Velphoro through their dialysis organization and will need pharmacy dispensing and a prescription.

• Peritoneal dialysis patients at home and those who have changed dialysis centers may experience a gap in their Velphoro supply as they navigate the new system.

Prior Authorization and Step Therapy Considerations

For patients who do require a pharmacy prescription (commercial insurance, certain Medicare Advantage plans), prior authorization is almost universally required. Most plans follow a step therapy protocol requiring documented failure of or contraindication to calcium acetate before approving Velphoro.

Key PA documentation points to include:

• Confirmed diagnosis of CKD on dialysis (ICD-10: N18.6) with hyperphosphatemia (serum phosphorus ≥5.5 mg/dL)

• History of hypercalcemia or elevated corrected calcium on calcium-based binders (justifies bypassing step therapy)

• Intolerance or inadequate response to step-therapy agents (calcium acetate or sevelamer)

• Documentation that patient is under care of or in consultation with a nephrologist (required by most payers)

• Documentation that Velphoro's lower pill burden is clinically necessary for adherence (particularly for elderly or cognitively impaired patients)

Clinically Appropriate Alternatives When Velphoro Is Unavailable

All phosphate binders have demonstrated equivalent efficacy in reducing serum phosphorus when patients are adherent. If Velphoro is temporarily unavailable or a PA is pending, the following alternatives are appropriate bridge options:

• Generic sevelamer carbonate (Renvela): Most accessible and affordable. Available at all major retail pharmacies. Non-calcium. Consider for patients without hypercalcemia concern. Typical starting dose 800-1,600 mg TID with meals; titrate to phosphorus target.

• Calcium acetate (PhosLo): Inexpensive, widely available. Use with caution in patients with hypercalcemia, low PTH (adynamic bone disease risk), or significant vascular calcification. Typical dose: 1,334 mg TID with meals.

• Ferric citrate (Auryxia): Consider when concurrent iron deficiency exists. May reduce ESA/IV iron requirements. Monitor potassium levels.

• Lanthanum carbonate (Fosrenol): Non-calcium, lower pill burden. Generic available. Good option for patients who struggle with sevelamer's pill burden but cannot access Velphoro.

Patient Assistance Programs Prescribers Should Know About

• Velphoro Access Solutions (Fresenius Medical Care): The official manufacturer PAP. Handles benefit investigations, PA initiation, and financial assistance. Fax applications to 1-866-496-8638. Eligibility varies.

• Velphoro Savings Card: For commercially insured patients. Reduces copay to $0 (up to $1,500 per prescription). Visit velphorocoupon.com.

• Velphoro Concierge Support (ASPN Pharmacies): For patients with a choice of pharmacy. Providers can fax prescriptions to 888-431-3403. Mail delivery included.

• New dialysis patient bridge: Patients who are new to dialysis with pending Medicare application may receive up to 90 days of Velphoro at no cost through a Fresenius program. Ask Access Solutions about eligibility.

How medfinder Can Help Your Patients

For patients with commercial insurance or Medicare Advantage who need to fill through a pharmacy, medfinder is a paid service that calls pharmacies on behalf of patients to identify which ones can fill their Velphoro prescription and texts results directly to the patient. This can cut hours of patient time and reduce your staff's call volume when patients report they can't find their medication.

Clinical Monitoring Reminders

• Monitor serum phosphorus at least monthly in patients on any phosphate binder

• If switching from Velphoro to another binder, re-titrate carefully — phosphate binding capacity per tablet differs significantly

• In patients who take levothyroxine concomitantly with Velphoro, ensure levothyroxine is taken at least 4 hours before Velphoro to prevent absorption interference

• Monitor iron homeostasis in patients at risk for iron overload (hemochromatosis, hepatic disease) on Velphoro

For a step-by-step guide on helping your patients access Velphoro, see our provider's guide to helping patients find Velphoro.